ABSTRACT
Introduction
Bimaxillary surgery results in a major volume of blood loss directly related to the operating time and the magnitude of the intervention. Recent studies have shown the deliberating effect of intravenous magnesium sulfate on hypotension. [1] [2] The reducing effect of magnesium sulfate on blood pressure is related to intervening in the activation of Ca ATPase and Na-K ATPase presuppose in trans-membranous ion exchange resulting in the stabilization of the cell membrane and cytoplasm microorganelles. [3] [4] Another physiological role of magnesium sulfate is related to the inhibition of calcium channels leading to limited calcium outflow from sarcoplasmic reticulum. [5] Magnesium sulfate can induce production and secretion of prostacyclin as well as reduce the activity of angiotensin converting enzyme leading to vasodilatation. [6] Moreover, the depressant influence of magnesium sulfate on the myocardium results in reduced heart contractility. [7] The collection of studies on the physiological effects of intravenous magnesium sulfate on hemodynamic status emphasizes its practical value in different clinical settings. These beneficial effects are more important following surgeries that lead to undesirable and unexpected hemodynamic changes such as reflex tachycardia, systemic hypertension, pulmonary artery hypertension, and also arrhythmias. [8] [9] In fact, the preoperative or intraoperative administration of intravenous magnesium sulfate has been approved as an accepted medication for stabilizing hemodynamic indices during surgery, especially through decreasing blood pressure and heart rate and also minimizing adverse hemodynamic responses. [10] Göral et al. [11] demonstrated that magnesium sulfate significantly decreased the amount of surgical bleeding by inducing controlled hypotension leading to less need for blood transfusion following lumbar discectomy surgery and improved surgical exposure without marked hemodynamic effects. However, magnesium sulfate should be used with caution in patients with renal dysfunction and is even prohibited in patients with myocardial injury or cardiac blocks. [12] Furthermore, when using magnesium sulfate, its side effects should also be considered such as possible complication during anesthesia and poorer surgical outcome. The blood loss during orthognathic surgery can be considerable. The reason for the extensive blood loss is the extensive vascularization of the maxillofacial region and access difficulty in terms of cauterization or ligation of the vessels involved. This bleeding is caused by the palatal large vessels (sphenopalatine artery and descending palatine artery), the pterygoid plexus, and the internal maxillary artery and its collateral branches to the upper jaw in Le Fort I osteotomies. The maxillary artery and its branches are the most vulnerable to injury during pterygomaxillary dysjunction or maxillary down fracture, specifically, the descending palatine artery. It can also be damaged if the maxilla is advanced to a significant degree, intruded posteriorly, or retruded. [13] This study aimed to assess the efficacy of intravenous magnesium sulfate on deliberating hypotension and bleeding in patients undergoing bimaxillary orthognathic surgery.
Material and Method

Study population
This randomized double-blinded placebo controlled trial The same anesthetic protocol was followed for all subjects. Propofol (2.5mg/kg) and remifentanil (3micro/ kg) were used for the induction. Propofol (100 micro/ kg /min) and remifentanil (0.1 micro/kg /min) were infused for anesthetic maintenance during the operation.
All subjects received N2O and O2 (50%) during the operation. The researcher physician and nurse who collected the data were unaware of the content of injected material (double blinded). The surgeon was also unaware of the types of administered drug. The randomization was performed by the random number generator and using permutation method. The sampling was also based on simple purposive method so if the selected person was not placed in the sample group, the other pe- 
Study measurements
Baseline characteristics including demographic characteristics, medical history, and anesthesia induction technique were collected by reviewing the recorded files.
All patients received 6 ml/kg serum Ringer and their vital signs were monitored. Intraoperative monitoring included ECG, peripheral oxygen saturation, and continues invasive intra-arterial blood pressure (typically measured at the radial artery) monitoring. Both systolic and diastolic blood pressures were measured before anesthesia induction (at baseline); during surgery, and also at the end of surgery. Each sample was constructed by selecting mean invasive arterial blood pressure sample from each of the selected patient trend records. Statistical significance of regression coefficients was determined based on 95% confidence intervals. Intraoperative blood loss was also determined by observing the volume of surgical suction bottles and all pieces of gauze were weighed at the end of the surgery and corrected by subtracting the amount of saline wash used during surgery. The incidence rates of bleeding, shivering, blood pressure changes, agitation and postoperative nausea and vomiting were also recorded after the surgery.
Statistical analysis
Results were presented as mean ± Standard deviation for quantitative variables and were summarized by absolute frequencies and percentages for categorical variables. Continuous variables were compared using t, and one-way ANOVA tests, or non-parametric MannWhitney U or Kruskal-Wallis tests whenever the data did not appear to have a normal distribution or when the assumption of equal variances was violated across the groups. Repeated-measure ANOVA test was also used to assess the difference in trend of the changes in systolic and diastolic blood pressures between the study groups adjusted for baseline variables including gender, age, body mass index and duration of surgery.
Data were analyzed using SPSS software version 20.0 (SPSS Inc., Chicago, IL). P values of 0.05 or less were considered statistically significant.
Results
We found no significant difference between the group receiving intravenous magnesium sulfate and the group receiving placebo, regarding the baseline variables such as gender distribution, mean age, and mean body mass index (Table 1) . However, in the magnesium sulfate group, there was a longer surgical time compared with the placebo group. Regarding intraoperative and postoperative events (Table 2 ), the volume of intraoperative blood loss and also blood products used for transfusion were similar in the two groups.
The total early sequela rate after surgery in the group receiving magnesium sulfate was 57.7% as compared with46.2% in the placebo group (p= 0.737). The most common complication in the post anesthesia care unit was shivering (30.8% versus 23.1%), followed by bleeding (11.5% versus 7.6%) and agitation (7.6% versus 11.5%). mg/kg/hr continuously during the operation. The pointed regimen reduced both systolic and diastolic blood pressure within operation without any significant changes in the volume of blood loss or required blood products; however, similar changes in both systolic and diastolic blood pressures were revealed in the placebo group. On the other hand, the change in both blood pressures was shown to be similar in both groups and also blood pressures were similarly compensated postoperatively in both groups. In total, administrating magnesium sulfate could not result in more reduction in both systolic and diastolic blood pressures compared with the control group within operation with no effect on the total amount of blood loss.
Reviewing the literature, we found contradictory results especially in terms of magnesium sulfate effect on blood loss or bleeding time. In a study by Elsharnouby et al., [14] a significant reduction of blood loss as well as mean arterial blood pressure was found in the group receiving magnesium sulfate. Sanders and Sim [15] reported increase in prothrombin time, and decrease in partial thromboplastin time after administrating magnesium sulfate. Prielipp and colleagues [16] reported that magnesium sulfate could blunt epinephrine's hypertensive action and prevent increase in mean arterial pressure during administration. Dabbagh et al.
[9] also showed that the magnesium group had less postoperative bleeding and less packed cell use compared with the placebo group, which is inconsistent with our findings. Furthermore, Nastou et al. [17] has been demonstrated that magnesium sulfate may act as a vasodilator with a minimal myocardial depression that could lower cardiac contractility as well as peripheral vascular resistance. [7, 18] The ability of this agent to inhibit the release of catecholamines has also been revealed. [19] [20] [21] Jee et al. [22] reported that norepinephrine, epinephrine, and vasopressin levels were lower in the magnesium group than in the control group.
However, these effects could not be revealed in our survey.
Although we could not demonstrate the effect of magnesium sulfate on the total amount of blood loss, reduced bleeding in some previous reports might be attributed to vasodilation or the systemic hypotensive effects of this drug. Also, the effects of the drug on coagulation system and platelet function, which leads to changes in bleeding time, has also been pointed, [23] [24] a finding which was not observed in our study. Since the effects of magnesium sulfate are dose-dependent, it seems that our employed dosage of this drug was not sufficient to lead to changes in bleeding or required blood products. In this context, the effects of the different dosages of magnesium sulfate on volume of blood loss and need for intraoperative blood transfusion should be further assessed in future studies.
One of the interesting points in our results is that despite the long duration of surgery in the magnesium sulfate group, the total amount of perioperative bleeding was similar in both groups. In fact, considering probable increasing intraoperative bleeding in prolonged operations, the use of magnesium sulfate may prevent perioperative bleeding appropriately. In some clinical studies on patients who underwent major surgeries, administrating intravenous magnesium sulfate lowered both perioperative and postoperative bleeding and packed cell use. [9] In total, it seems that in order to achieve correct results about the impact of intravenous magnesium sulfate on perioperative bleeding or needing blood transfusion, different time points of surgery duration in future studies should be considered. As magnesium is a natural physiological calcium antagonist and regulates calcium influx into cells, it may affect the coagulation cascade.
[ [24] [25] It is recommended that in future studies coagulation profile tests should be determined in these patients.
Conclusion
The administration of intravenous magnesium sulfate can attenuate both systolic and diastolic blood pressures during bimaxillary orthognathic surgery with no significant effect on blood loss or needing blood products.
Despite the long duration of surgery in the magnesium sulfate group, the total amount of perioperative bleeding was similar in both groups. Because of the nature of dose-dependent effects of magnesium sulfate, its effects on hemodynamic parameter may be different in different used dosages and prescribed protocols.
